Search research articles
Contact Us
Filters
Showing results (111-120 of 176) with videos related to
Page
of 18
Sort By:
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
Clinical Genitourinary Cancer
|
May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium
Lauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2019
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Lawrence Fong, Michael J Morris, Oliver Sartor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
The Oncologist
|
June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
Elisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Clinical Genitourinary Cancer
|
January 14, 2020
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
J Connor Wells, Jeffrey Graham, Benoit Beuselinck, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 176) with videos related to
Sort By:
Page
of 18
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
Clinical Genitourinary Cancer
|
May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium
Lauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2019
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Lawrence Fong, Michael J Morris, Oliver Sartor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
The Oncologist
|
June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
Elisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Clinical Genitourinary Cancer
|
January 14, 2020
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
J Connor Wells, Jeffrey Graham, Benoit Beuselinck, et al.
Page
of 18